Institutional investors purchased a net $2.4 million shares of INSM during the quarter ended September 2015 and now own 92.91% of the total shares outstanding. This majority interest is a greater percentage than is typical for companies in the Biotechnology industry and highlights that the smart money sees this stock as an important holding.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
ORBIMED ADVISORS LLC Bought 1.4 Million shares of Insmed Inc
THE VANGUARD GROUP, INC. Bought 1.0 Million shares of Insmed Inc
T. ROWE PRICE ASSOCIATES, INC. Bought 387.8 Thousand shares of Insmed Inc